OncoMatch/Clinical Trials/NCT06828328
A Study of GC203 TIL in PDCA (RJ)
Is NCT06828328 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies GC203 TIL for pancreatic cancer.
Treatment: GC203 TIL — This study is to investigate the safety and efficacy of gene-edited tumor infiltrating lymphocyte (GC203 TIL) therapy in patients with pancreatic ductal adenocarcinoma. Gene-edited TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard treatment regimens
Test subjects have failed standard treatment regimens
Cannot have received: allogeneic T cell therapy
History of allogeneic T cell therapy
Cannot have received: allogeneic stem cell transplantation
History of organ transplantation, allogeneic stem cell transplantation, and renal replacement therapy
Cannot have received: renal replacement therapy
History of organ transplantation, allogeneic stem cell transplantation, and renal replacement therapy
Lab requirements
Blood counts
Absolute count of white blood cells ≥2.5×10^9/L; Absolute count of neutrophils ≥1.5×10^9/L; Absolute count of lymphocytes ≥0.7×10^9/L; Platelet count ≥90×10^9; hemoglobin ≥90 g/L; Activated partial thromboplastin time (APTT) ≤1.5xULN (unless received anticoagulant therapy within the previous 3 days); International normalized ratio (INR) ≤1.5xULN (unless received anticoagulant therapy within the previous 3 days)
Kidney function
Serum creatinine ≤1.5mg/dL (or ≤132.6μmol/L), or clearance rate ≥50mL/min
Liver function
Serum ALT/AST ≤3×ULN (subjects with liver metastasis ≤3×ULN); Total bilirubin ≤1.5×ULN
Cardiac function
No NYHA Grade III or IV congestive heart failure, no clinically significant low blood pressure, no uncontrollable symptomatic coronary artery diseases, ejection fraction ≥35%; no severe cardiac rhythm and conduction anomaly (e.g., ventricular arrhythmia requiring clinical intervention, second-third degree atrio-ventricular conductive block)
Hematology and Chemistry（within 7 days prior to enrollment）: Absolute count of white blood cells≥2.5×10^9/L; Absolute count of neutropils≥1.5×10^9/L; Absolute count of lymphocytes ≥0.7×10^9/L； Platelet count≥90×10^9； hemoglobin≥90 g/L; Activated partial thromboplastin time (APTT) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days); International normalized ratio (INR) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days); Serum creatinine ≤1.5mg/dL(or ≤132.6μmol/L), or clearance rate≥50mL/min; Serum ALT/AST ≤3×ULN(subjects with liver metastasis ≤3×ULN); Totol bilirubin≤1.5×ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify